Ulk1 Can Suppress Or Promote Tumor Growth Under Different Conditions

Tian Mao,Ouyang Liang
DOI: https://doi.org/10.1016/B978-0-12-805420-8.00012-3
2017-01-01
Abstract:Unc-51-like protein kinase 1 (ULK1), the mammalian homology of Atg1, is not only the initial protein during autophagy but also the exclusive serine/threonine protein kinase so far identified in the core autophagic pathway. Autophagy can be normally divided into five stages: induction, vesicle nucleation, vesicle elongation, docking and fusion, degradation and recycling. Activation of ULK1 by upstream signals, including AMPK and mTOR, can trigger autophagy under different stress conditions. ULK1, FIP200, mAtg13, and Atg101 form a protein complex that can be regulated by posttranslational modifications, such as phosphorylation and acetylation. In addition the common downstream regulator of ULK1 complex includes the phosphoinositide 3-kinase (PI3K) class III-Beclin-1 complex. Interestingly, both the transcriptional regulations of ULK1 complex and posttranscriptional modifications of it varies in different cancers, making ULK1 a promising therapeutic target and a diagnostic marker. In addition, considering the dual role of autophagy across various cancers, ULK1 can either promote tumor development or suppress tumor growth based on distinct conditions. Recently, few small-molecule compounds have been discovered that can target ULK1 with antitumor capacities. Therefore the elucidation of the function of ULK1 in cancer should benefit the future discovery of novel antitumor drugs and the combination therapy in cancers.
What problem does this paper attempt to address?